ESR1 and breast cancer: As evidenced by the fact that ERα-negative breast cancer sheltered from endocrine therapy previously acquired arousable sensitivity to tamoxifen (5), it was implied that the endocrine response promised to be a novel mechanism in TNBC, which the absence of hormone receptors could not overshadow.